April 5, 2010 (FinancialWire) — K-V Pharmaceutical Co. (NYSE: KV-B) said that it has reduced its work force by 289 employees, or around 42%, in order to lower its operating costs.

According to K-V, the reduction is a part of the company's efforts to manage its cash and financial resources while it continues working with the Food and Drug Administration to return its products to market.

K-V Pharmaceutical is a specialty pharmaceutical company that develops, manufactures, markets, and acquires branded and generic/non-branded prescription pharmaceutical products.

(For more biomedical and/or phamaceutical related articles go to http://www.financialwire.net/?s=biomedphrm)

(For more “economy’s impact” articles go to http://www.financialwire.net/?s=ecnmysmpct)

(For more business restructuring articles go to http://www.financialwire.net/?s=restrctrng)

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[biomedphrm] [ecnmysmpct] [restrctrng]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.